A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
Stefano Cascinu(University of Modena and Reggio Emilia), Giuseppina Catalano(The Ohio State University), Claudio Graiff(Ospedale di Bolzano), Vincenzo Catalano(Azienda Ospedaliero-Universitaria delle Marche), S. Zonato, Sandro Barni, Roberto Labianca(Ospedale Papa Giovanni XXIII), Giovanni Picone(Ospedale di Parma), M.A. Pessi(Ospedale San Carlo), Fabio Farinati(University of Padua), C.G. Curti(Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente), L. Frontini
Cited by 36
Related Papers
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k
Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials
|Journal of Clinical Oncology|2008|582
DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
|JNCI Journal of the National Cancer Institute|2011|527